MSH2 and cancer: In Group 1, individuals at risk of cancer from families with path_MLH1 variants mainly developed CRC (116/195; 59.5%) rather than extracolonic tumors (79/195; 40.5%), while individuals from families with path_MSH2 showed CRC (47/99; 47.5%) and extracolonic tumors (52/99; 52.5%) equally (Table 3) (chi-square test p = 0.05018).